Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson’s disease
•PROTO showed improvement in visual and motor function ability in rat model.•PROTO increases nuclear expression of Nrf2 and its transcriptional activity in SH-SY5Y cells.•PROTO showed neuroprotective effects against PD. Parkinson’s disease (PD) is the most widespread motor-affecting disease affectin...
Gespeichert in:
| Veröffentlicht in: | Pharmacological reports 2018-02, Vol.70 (1), p.139-145 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 145 |
|---|---|
| container_issue | 1 |
| container_start_page | 139 |
| container_title | Pharmacological reports |
| container_volume | 70 |
| creator | Wu, Jing Zhao, Yu-Mei Deng, Zhi-Kuan |
| description | •PROTO showed improvement in visual and motor function ability in rat model.•PROTO increases nuclear expression of Nrf2 and its transcriptional activity in SH-SY5Y cells.•PROTO showed neuroprotective effects against PD.
Parkinson’s disease (PD) is the most widespread motor-affecting disease affecting majorly middle- and late age population. Thus, in the current study, we intended to explore the neuroprotective effect of protodioscin (Proto) against 6-hydroxydopamine (6-OHDA)-induced PD rat model.
After induction of PD with the injection of 6-OHDA, the different dose of Proto was administered for the duration of experimental protocol (2 months). We have scrutinized the consequence of Proto on the cognitive behaviours via Moris water maze (MWM), and recognition of novel objects and its location tasks. The effect of Proto was also investigated on the expression of Nrf2 in human neuroblastoma SHSY5Y cells via western blot analysis.
The results showed significant decrease in travelled distance as compared by the lesion treated group. Further significant difference was revealed in the latency time to detect the platform that is visible and it confirmed that, there were no noteworthy dissimilarity was observed in the visual and motor function ability. The result also suggests that, the activation of Nrf2 is the possible mechanism of neuroprotection of Proto against PD.
As a concluding remark, the present study confirmed the neuroprotective role of Proto against PD both in in vitro and in vivo models. |
| doi_str_mv | 10.1016/j.pharep.2017.08.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1991186959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S173411401730419X</els_id><sourcerecordid>1991186959</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-6a9dfa86592d2678c0ce03865e88be8d737124820ec924fe3a9a4984241b6db53</originalsourceid><addsrcrecordid>eNqFkc9u3CAQh1HVqNmkfYOq8rEXO4CxDZdKVZR_UpTkkJ7RLIwTtjZswV4pt7xGX69PErZOe2xPI5jvN8AHIR8ZrRhl7cmm2j5CxG3FKesqKivK6jdkxblSZdNK8ZasWFeLkjFBD8lRShtKBeN1844cclW3XZ6yIsMNzjFsY5jQTG6HBeQSfAHeFiOaR_AuTc4UuINhht-t0Bd7PlgXknEZfQDn01REmIoxWBz2xB3E73k3-F_PP1NhXUJI-J4c9DAk_PBaj8m387P708vy-vbi6vTrdWlEJ6ayBWV7kG2juOVtJw01SOu8RinXKG1Xd4wLySkaxUWPNSgQSgou2Lq166Y-Jp-XufmeP2ZMkx5dMjgM4DHMSTOlGJOtalRGxYKaGFKK2OttdCPEJ82o3nvWG7141nvPmkqdPefYp9cT5vWI9m_oj9gMNAuQcss_YNSbMEefX_2_wV-WHGY_O5dz2TF6g9bF_EPaBvfvAS9xeqTt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1991186959</pqid></control><display><type>article</type><title>Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson’s disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wu, Jing ; Zhao, Yu-Mei ; Deng, Zhi-Kuan</creator><creatorcontrib>Wu, Jing ; Zhao, Yu-Mei ; Deng, Zhi-Kuan</creatorcontrib><description>•PROTO showed improvement in visual and motor function ability in rat model.•PROTO increases nuclear expression of Nrf2 and its transcriptional activity in SH-SY5Y cells.•PROTO showed neuroprotective effects against PD.
Parkinson’s disease (PD) is the most widespread motor-affecting disease affecting majorly middle- and late age population. Thus, in the current study, we intended to explore the neuroprotective effect of protodioscin (Proto) against 6-hydroxydopamine (6-OHDA)-induced PD rat model.
After induction of PD with the injection of 6-OHDA, the different dose of Proto was administered for the duration of experimental protocol (2 months). We have scrutinized the consequence of Proto on the cognitive behaviours via Moris water maze (MWM), and recognition of novel objects and its location tasks. The effect of Proto was also investigated on the expression of Nrf2 in human neuroblastoma SHSY5Y cells via western blot analysis.
The results showed significant decrease in travelled distance as compared by the lesion treated group. Further significant difference was revealed in the latency time to detect the platform that is visible and it confirmed that, there were no noteworthy dissimilarity was observed in the visual and motor function ability. The result also suggests that, the activation of Nrf2 is the possible mechanism of neuroprotection of Proto against PD.
As a concluding remark, the present study confirmed the neuroprotective role of Proto against PD both in in vitro and in vivo models.</description><identifier>ISSN: 1734-1140</identifier><identifier>EISSN: 2299-5684</identifier><identifier>DOI: 10.1016/j.pharep.2017.08.013</identifier><identifier>PMID: 29367101</identifier><language>eng</language><publisher>Cham: Elsevier B.V</publisher><subject>6-OHDA ; Animals ; Behavior, Animal - drug effects ; Brain - drug effects ; Brain - metabolism ; Brain - physiopathology ; Cell Line, Tumor ; Cognition - drug effects ; Dihydroxyphenylalanine - analogs & derivatives ; Diosgenin - analogs & derivatives ; Diosgenin - pharmacology ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Drug Safety and Pharmacovigilance ; Exploratory Behavior - drug effects ; Humans ; Male ; Maze Learning - drug effects ; Neuroprotective Agents - pharmacology ; NF-E2-Related Factor 2 - metabolism ; NOR ; Nrf2 ; Original Article ; Parkinsonian Disorders - chemically induced ; Parkinsonian Disorders - metabolism ; Parkinsonian Disorders - prevention & control ; Parkinsonian Disorders - psychology ; Parkinson’s disease ; Pharmacotherapy ; Pharmacy ; Rats, Wistar ; Saponins - pharmacology ; SH-SY5Y cell</subject><ispartof>Pharmacological reports, 2018-02, Vol.70 (1), p.139-145</ispartof><rights>2017 Institute of Pharmacology, Polish Academy of Sciences</rights><rights>Maj Institute of Pharmacology Polish Academy of Sciences 2017</rights><rights>Copyright © 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-6a9dfa86592d2678c0ce03865e88be8d737124820ec924fe3a9a4984241b6db53</citedby><cites>FETCH-LOGICAL-c474t-6a9dfa86592d2678c0ce03865e88be8d737124820ec924fe3a9a4984241b6db53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1016/j.pharep.2017.08.013$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1016/j.pharep.2017.08.013$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29367101$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Zhao, Yu-Mei</creatorcontrib><creatorcontrib>Deng, Zhi-Kuan</creatorcontrib><title>Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson’s disease</title><title>Pharmacological reports</title><addtitle>Pharmacol. Rep</addtitle><addtitle>Pharmacol Rep</addtitle><description>•PROTO showed improvement in visual and motor function ability in rat model.•PROTO increases nuclear expression of Nrf2 and its transcriptional activity in SH-SY5Y cells.•PROTO showed neuroprotective effects against PD.
Parkinson’s disease (PD) is the most widespread motor-affecting disease affecting majorly middle- and late age population. Thus, in the current study, we intended to explore the neuroprotective effect of protodioscin (Proto) against 6-hydroxydopamine (6-OHDA)-induced PD rat model.
After induction of PD with the injection of 6-OHDA, the different dose of Proto was administered for the duration of experimental protocol (2 months). We have scrutinized the consequence of Proto on the cognitive behaviours via Moris water maze (MWM), and recognition of novel objects and its location tasks. The effect of Proto was also investigated on the expression of Nrf2 in human neuroblastoma SHSY5Y cells via western blot analysis.
The results showed significant decrease in travelled distance as compared by the lesion treated group. Further significant difference was revealed in the latency time to detect the platform that is visible and it confirmed that, there were no noteworthy dissimilarity was observed in the visual and motor function ability. The result also suggests that, the activation of Nrf2 is the possible mechanism of neuroprotection of Proto against PD.
As a concluding remark, the present study confirmed the neuroprotective role of Proto against PD both in in vitro and in vivo models.</description><subject>6-OHDA</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Brain - physiopathology</subject><subject>Cell Line, Tumor</subject><subject>Cognition - drug effects</subject><subject>Dihydroxyphenylalanine - analogs & derivatives</subject><subject>Diosgenin - analogs & derivatives</subject><subject>Diosgenin - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Exploratory Behavior - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Maze Learning - drug effects</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>NF-E2-Related Factor 2 - metabolism</subject><subject>NOR</subject><subject>Nrf2</subject><subject>Original Article</subject><subject>Parkinsonian Disorders - chemically induced</subject><subject>Parkinsonian Disorders - metabolism</subject><subject>Parkinsonian Disorders - prevention & control</subject><subject>Parkinsonian Disorders - psychology</subject><subject>Parkinson’s disease</subject><subject>Pharmacotherapy</subject><subject>Pharmacy</subject><subject>Rats, Wistar</subject><subject>Saponins - pharmacology</subject><subject>SH-SY5Y cell</subject><issn>1734-1140</issn><issn>2299-5684</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u3CAQh1HVqNmkfYOq8rEXO4CxDZdKVZR_UpTkkJ7RLIwTtjZswV4pt7xGX69PErZOe2xPI5jvN8AHIR8ZrRhl7cmm2j5CxG3FKesqKivK6jdkxblSZdNK8ZasWFeLkjFBD8lRShtKBeN1844cclW3XZ6yIsMNzjFsY5jQTG6HBeQSfAHeFiOaR_AuTc4UuINhht-t0Bd7PlgXknEZfQDn01REmIoxWBz2xB3E73k3-F_PP1NhXUJI-J4c9DAk_PBaj8m387P708vy-vbi6vTrdWlEJ6ayBWV7kG2juOVtJw01SOu8RinXKG1Xd4wLySkaxUWPNSgQSgou2Lq166Y-Jp-XufmeP2ZMkx5dMjgM4DHMSTOlGJOtalRGxYKaGFKK2OttdCPEJ82o3nvWG7141nvPmkqdPefYp9cT5vWI9m_oj9gMNAuQcss_YNSbMEefX_2_wV-WHGY_O5dz2TF6g9bF_EPaBvfvAS9xeqTt</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Wu, Jing</creator><creator>Zhao, Yu-Mei</creator><creator>Deng, Zhi-Kuan</creator><general>Elsevier B.V</general><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson’s disease</title><author>Wu, Jing ; Zhao, Yu-Mei ; Deng, Zhi-Kuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-6a9dfa86592d2678c0ce03865e88be8d737124820ec924fe3a9a4984241b6db53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>6-OHDA</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Brain - physiopathology</topic><topic>Cell Line, Tumor</topic><topic>Cognition - drug effects</topic><topic>Dihydroxyphenylalanine - analogs & derivatives</topic><topic>Diosgenin - analogs & derivatives</topic><topic>Diosgenin - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Exploratory Behavior - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Maze Learning - drug effects</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>NF-E2-Related Factor 2 - metabolism</topic><topic>NOR</topic><topic>Nrf2</topic><topic>Original Article</topic><topic>Parkinsonian Disorders - chemically induced</topic><topic>Parkinsonian Disorders - metabolism</topic><topic>Parkinsonian Disorders - prevention & control</topic><topic>Parkinsonian Disorders - psychology</topic><topic>Parkinson’s disease</topic><topic>Pharmacotherapy</topic><topic>Pharmacy</topic><topic>Rats, Wistar</topic><topic>Saponins - pharmacology</topic><topic>SH-SY5Y cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Zhao, Yu-Mei</creatorcontrib><creatorcontrib>Deng, Zhi-Kuan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacological reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Jing</au><au>Zhao, Yu-Mei</au><au>Deng, Zhi-Kuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson’s disease</atitle><jtitle>Pharmacological reports</jtitle><stitle>Pharmacol. Rep</stitle><addtitle>Pharmacol Rep</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>70</volume><issue>1</issue><spage>139</spage><epage>145</epage><pages>139-145</pages><issn>1734-1140</issn><eissn>2299-5684</eissn><abstract>•PROTO showed improvement in visual and motor function ability in rat model.•PROTO increases nuclear expression of Nrf2 and its transcriptional activity in SH-SY5Y cells.•PROTO showed neuroprotective effects against PD.
Parkinson’s disease (PD) is the most widespread motor-affecting disease affecting majorly middle- and late age population. Thus, in the current study, we intended to explore the neuroprotective effect of protodioscin (Proto) against 6-hydroxydopamine (6-OHDA)-induced PD rat model.
After induction of PD with the injection of 6-OHDA, the different dose of Proto was administered for the duration of experimental protocol (2 months). We have scrutinized the consequence of Proto on the cognitive behaviours via Moris water maze (MWM), and recognition of novel objects and its location tasks. The effect of Proto was also investigated on the expression of Nrf2 in human neuroblastoma SHSY5Y cells via western blot analysis.
The results showed significant decrease in travelled distance as compared by the lesion treated group. Further significant difference was revealed in the latency time to detect the platform that is visible and it confirmed that, there were no noteworthy dissimilarity was observed in the visual and motor function ability. The result also suggests that, the activation of Nrf2 is the possible mechanism of neuroprotection of Proto against PD.
As a concluding remark, the present study confirmed the neuroprotective role of Proto against PD both in in vitro and in vivo models.</abstract><cop>Cham</cop><pub>Elsevier B.V</pub><pmid>29367101</pmid><doi>10.1016/j.pharep.2017.08.013</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1734-1140 |
| ispartof | Pharmacological reports, 2018-02, Vol.70 (1), p.139-145 |
| issn | 1734-1140 2299-5684 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1991186959 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 6-OHDA Animals Behavior, Animal - drug effects Brain - drug effects Brain - metabolism Brain - physiopathology Cell Line, Tumor Cognition - drug effects Dihydroxyphenylalanine - analogs & derivatives Diosgenin - analogs & derivatives Diosgenin - pharmacology Disease Models, Animal Dose-Response Relationship, Drug Drug Safety and Pharmacovigilance Exploratory Behavior - drug effects Humans Male Maze Learning - drug effects Neuroprotective Agents - pharmacology NF-E2-Related Factor 2 - metabolism NOR Nrf2 Original Article Parkinsonian Disorders - chemically induced Parkinsonian Disorders - metabolism Parkinsonian Disorders - prevention & control Parkinsonian Disorders - psychology Parkinson’s disease Pharmacotherapy Pharmacy Rats, Wistar Saponins - pharmacology SH-SY5Y cell |
| title | Neuroprotective action and mechanistic evaluation of protodioscin against rat model of Parkinson’s disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A01%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuroprotective%20action%20and%20mechanistic%20evaluation%20of%20protodioscin%20against%20rat%20model%20of%20Parkinson%E2%80%99s%20disease&rft.jtitle=Pharmacological%20reports&rft.au=Wu,%20Jing&rft.date=2018-02-01&rft.volume=70&rft.issue=1&rft.spage=139&rft.epage=145&rft.pages=139-145&rft.issn=1734-1140&rft.eissn=2299-5684&rft_id=info:doi/10.1016/j.pharep.2017.08.013&rft_dat=%3Cproquest_cross%3E1991186959%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1991186959&rft_id=info:pmid/29367101&rft_els_id=S173411401730419X&rfr_iscdi=true |